Date Title Document
Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance Date 12/15/14 Title Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance Download PDF
Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 Date 11/28/14 Title Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 Download PDF
Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris Date 11/25/14 Title Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris Download PDF
Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program Date 11/20/14 Title Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program Download PDF
Valeant Comments On Allergan Announcement Date 11/17/14 Title Valeant Comments On Allergan Announcement Download PDF
Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey Date 11/13/14 Title Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey Download PDF
Valeant Pharmaceuticals Sends Letter To Physician Customers Date 11/07/14 Title Valeant Pharmaceuticals Sends Letter To Physician Customers Download PDF
Valeant And Pershing Square May Vote At Special Meeting Date 11/04/14 Title Valeant And Pershing Square May Vote At Special Meeting Download PDF
Valeant Delivers Letter To Allergan Board Date 10/27/14 Title Valeant Delivers Letter To Allergan Board Download PDF
Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results Date 10/20/14 Title Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results Download PDF
Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014 Date 10/15/14 Title Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014 Download PDF
Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA Date 09/30/14 Title Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA Download PDF
Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% Date 09/26/14 Title Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% Download PDF
Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO™ (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies Date 09/25/14 Title Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO™ (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies Download PDF
Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals Date 09/25/14 Title Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals Download PDF
Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director Date 09/24/14 Title Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director Download PDF
Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 Date 09/15/14 Title Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 Download PDF
Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester Date 09/08/14 Title Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester Download PDF
Valeant Extends Offer To Acquire Allergan Date 08/15/14 Title Valeant Extends Offer To Acquire Allergan Download PDF
Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino Date 08/11/14 Title Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino Download PDF
Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders Date 08/06/14 Title Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders Download PDF
Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit Date 08/01/14 Title Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit Download PDF
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results (pdf version) Date 07/31/14 Title Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results (pdf version) Download pdf
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results Date 07/31/14 Title Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results Download PDF
Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements Date 07/24/14 Title Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements Download PDF
Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements Date 07/21/14 Title Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements Download PDF
Valeant Pharmaceuticals Files Investor Presentation Date 07/18/14 Title Valeant Pharmaceuticals Files Investor Presentation Download PDF
Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure Date 07/17/14 Title Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure Download PDF
Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan Date 07/14/14 Title Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan Download PDF
Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma Date 07/10/14 Title Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma Download PDF
Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology Date 07/08/14 Title Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology Download PDF
Valeant Files Preliminary Proxy Statement for Special Meeting of Shareholders to Approve Share Issuance in Proposed Acquisition of Allergan Date 06/25/14 Title Valeant Files Preliminary Proxy Statement for Special Meeting of Shareholders to Approve Share Issuance in Proposed Acquisition of Allergan Download PDF
Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements Date 06/23/14 Title Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements Download PDF
Valeant Commences Exchange Offer For Allergan Date 06/18/14 Title Valeant Commences Exchange Offer For Allergan Download PDF
Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk Date 06/16/14 Title Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk Download PDF
Valeant Pharmaceuticals To Hold Conference Call On Tuesday, June 17, 2014 To Correct Recent Misrepresentations Date 06/13/14 Title Valeant Pharmaceuticals To Hold Conference Call On Tuesday, June 17, 2014 To Correct Recent Misrepresentations Download PDF
Valeant Pharmaceuticals Announces Planned Management Departure Date 06/13/14 Title Valeant Pharmaceuticals Announces Planned Management Departure Download PDF
Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis Date 06/09/14 Title Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis Download PDF
Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations Date 05/30/14 Title Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations Download PDF
Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billion Date 05/28/14 Title Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billion Download PDF
Valeant Substantially Increases Merger Proposal For Allergan Date 05/28/14 Title Valeant Substantially Increases Merger Proposal For Allergan Download PDF
Valeant To Host In-Person Investor Meeting And Webcast On May 28, 2014 At 8:00 A.M. ET Date 05/27/14 Title Valeant To Host In-Person Investor Meeting And Webcast On May 28, 2014 At 8:00 A.M. ET Download PDF
Valeant Pharmaceuticals to Present at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 Date 05/23/14 Title Valeant Pharmaceuticals to Present at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 Download PDF
Valeant Pharmaceuticals Announces 2014 Annual Meeting Results Date 05/21/14 Title Valeant Pharmaceuticals Announces 2014 Annual Meeting Results Download PDF
Valeant to Discuss Allergan Proposal at Investor Meeting and Webcast on May 28, 2014 at 8:00 A.M. ET Date 05/20/14 Title Valeant to Discuss Allergan Proposal at Investor Meeting and Webcast on May 28, 2014 at 8:00 A.M. ET Download PDF
Valeant Pharmaceuticals Responds to Allergan's Rejection of Merger Proposal Date 05/13/14 Title Valeant Pharmaceuticals Responds to Allergan's Rejection of Merger Proposal Download PDF
Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis Date 05/12/14 Title Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis Download PDF
Valeant Pharmaceuticals Reports First Quarter 2014 Financial Results Date 05/08/14 Title Valeant Pharmaceuticals Reports First Quarter 2014 Financial Results Download PDF
Valeant Pharmaceuticals To Webcast 2014 Annual Meeting Of Shareholders Date 05/01/14 Title Valeant Pharmaceuticals To Webcast 2014 Annual Meeting Of Shareholders Download PDF
Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available Date 04/24/14 Title Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available Download PDF
Valeant Pharmaceuticals To Announce 2014 First Quarter Results On May 8, 2014 Date 04/24/14 Title Valeant Pharmaceuticals To Announce 2014 First Quarter Results On May 8, 2014 Download PDF
Valeant Pharmaceuticals Announces Nominations For Board Of Directors Date 04/23/14 Title Valeant Pharmaceuticals Announces Nominations For Board Of Directors Download PDF
Valeant Proposes to Combine With Allergan for $48.30 in Cash and 0.83 Shares of Valeant Stock for Each Allergan Share Date 04/22/14 Title Valeant Proposes to Combine With Allergan for $48.30 in Cash and 0.83 Shares of Valeant Stock for Each Allergan Share Download PDF
Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% Date 03/25/14 Title Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% Download PDF
Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results Date 02/27/14 Title Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results Download PDF
Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014 Date 02/05/14 Title Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014 Download PDF
Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million Date 02/03/14 Title Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million Download PDF
Valeant Pharmaceuticals Announces Approval of Retin-A Micro® Microsphere 0.08% Date 01/31/14 Title Valeant Pharmaceuticals Announces Approval of Retin-A Micro® Microsphere 0.08% Download PDF
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc. Date 01/23/14 Title Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc. Download PDF
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Solta Medical, Inc. Date 01/23/14 Title Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Solta Medical, Inc. Download PDF
Valeant Pharmaceuticals Announces New $1.5 Billion Securities Repurchase Program Date 01/22/14 Title Valeant Pharmaceuticals Announces New $1.5 Billion Securities Repurchase Program Download PDF
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. Date 01/15/14 Title Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. Download PDF
Annual Report

2015 Annual Report

The right products
The right philosophy.
record organic growth.

View All